NasdaqCM - Delayed Quote USD

Genelux Corporation (GNLX)

2.7900

+0.1700

(+6.49%)

At close: May 28 at 4:00 PM EDT

2.7998

+0.01

(+0.35%)

After hours: May 28 at 7:29 PM EDT

Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop

Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop

PREMIUM
MT Newswires 4 days ago

GNLX
+6.49%
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions. Each warrant will have an exercise price of

GlobeNewswire 4 days ago

GNLX
+6.49%
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock s

GlobeNewswire 5 days ago

GNLX
+6.49%
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. “Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Looking ahead, we are excited about advancing Olvi-Vec into a

GlobeNewswire 19 days ago

GNLX
+6.49%
Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders

Key Insights Significant control over Genelux by individual investors implies that the general public has more power to...

Simply Wall St. 23 days ago

GNLX
+6.49%
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

GNLX
+6.49%
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Genelux Corporation (GNLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

GNLX
+6.49%
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)

Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks last month

GNLX
+6.49%
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy

Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

GNLX
+6.49%
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation of Phase 2 trial in non-small cell lung cancer (recurrent/platinum-ICI failure) with systemic administration of Olvi-Vec expected in 1H 2024 – – Ongoing Phase 1b/2 trial with systemic administration of Olvi-Vec in small cell lung cancer expected interim readout in 2H 2024 – – $23.2 million in cash, cash

GlobeNewswire last month

GNLX
+6.49%
Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)

In the realm of stock market movements, insider trading activity is often a significant indicator for investors.

GuruFocus.com 5 months ago

GNLX
+6.49%
$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administrat

GlobeNewswire 5 months ago

GNLX
+6.49%
Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%

Key Insights Significant control over Genelux by retail investors implies that the general public has more power to...

Simply Wall St. 6 months ago

GNLX
+6.49%
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. “The third quarter was highlighted by continued expansi

GlobeNewswire 6 months ago

GNLX
+6.49%
12 Best Performing Biotech Stocks in 2023

In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […]

Insider Monkey 7 months ago

IMGN

MLTX

BBIO
Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX)

On September 18, 2023, John Thomas, a director at Genelux Corp (NASDAQ:GNLX), sold 6,667 shares of the company.

GuruFocus.com 8 months ago

GNLX
+6.49%
Director John Smither Sells 900 Shares of Genelux Corp (GNLX)

On September 13, 2023, John Smither, a director at Genelux Corp (NASDAQ:GNLX), sold 900 shares of the company's stock.

GuruFocus.com 8 months ago

GNLX
+6.49%
10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)

On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp (NASDAQ:GNLX).

GuruFocus.com 8 months ago

GNLX
+6.49%
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company’s 2023 Inducement Plan, including an option to purchase 150,000 shares of common stock to Lourie Zak, the Company

GlobeNewswire 8 months ago

GNLX
+6.49%
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023. The Company will also attend virtual one-on-one meetings during the conference. Institutional investors interested in a

GlobeNewswire 8 months ago

GNLX
+6.49%

Performance Overview

Return	GNLX	S&P 500
YTD	-80.09%	+11.24%
1-Year	-88.37%	+26.17%
3-Year	-53.50%	+30.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genelux Corporation (GNLX)

Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders

Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround

After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)

All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

12 Best Performing Biotech Stocks in 2023

Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX)

Director John Smither Sells 900 Shares of Genelux Corp (GNLX)

10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Performance Overview